Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | SMARCA4 |
Variant | loss |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | SMARCA4 loss indicates loss of the SMARCA4 gene, mRNA, and protein. |
Associated Drug Resistance | |
Category Variants Paths |
SMARCA4 mutant SMARCA4 inact mut SMARCA4 loss |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCA4 loss | Advanced Solid Tumor | not applicable | N/A | Preclinical | Emerging | In a preclinical study, siRNA knockdown of BRM in SMARCA4-deficient tumor cells resulted in decreased growth and viability, suggesting that inhibition of BRM may be a promising therapeutic approach for targeting tumors with SMARCA4 loss (PMID: 23872584). | 23872584 |
SMARCA4 loss | lung non-small cell carcinoma | sensitive | Tozasertib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung cancer cell lines with SMARCA4 loss demonstrated increased sensitivity to Tozasertib (VX-680), compared to cell lines expressing wild-type SMARCA4, in culture (Cancer Res July 15 2016 (76) (14 Supplement) LB-318). | detail... |
SMARCA4 loss | Advanced Solid Tumor | predicted - sensitive | PRT7732 | Preclinical - Cell culture | Actionable | In a preclinical study, PRT7732 inhibited proliferation of SMARCA4-deficient cancer cell lines in culture (Cancer Res (2024) 84 (6_Supplement): 4503). | detail... |
SMARCA4 loss | lung cancer | predicted - sensitive | PRT7732 | Preclinical | Actionable | In a preclinical study, PRT7732 inhibited tumor growth in a SMARCA4-deficient lung cancer xenograft model (Cancer Res (2024) 84 (6_Supplement): 4503). | detail... |